Shortening drug development cycles is a primary goal in Eastern and Western countries alike. Integrated bioinformatics and chemoinformatics approaches are known to facilitate investigation of therapeutic targets and identification of drug-like compounds. Indeed, recent reports suggest that computational methods can save about 2-3 years and significantly lower the cost of the overall process.

Our project entitled holistic in silico approaches to support effective design of Therapeutic Molecules (abbreviated MTi in French) aims at:

• the development of new methods in the fields of bioinformatics and chemoinformatics.
• the identification of small bio-active chemical compounds using in silico screening experiments.
• the validation of new therapeutic targets through bioinformatics strategies.
• providing free computer packages to the scientific community.
• MTi has tight collaborations with two IBiSA platforms called RPBS (structural bioinformatics) and cDithem (drug discovery).